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TFIID plays a role in nucleating RNA polymerase II preinitiation complex assembly on protein-coding genes. TFIID is
a multisubunit complex comprised of the TATA box binding protein (TBP) and 14 TBP-associated factors (TAFs). Another class
of multiprotein transcriptional regulatory complexes having histone acetyl transferase (HAT) activity, and containing TAFs,
includes TFTC, STAGA and the PCAF/GCN5 complex. Looking for as yet undiscovered subunits by a proteomic approach, we
had identified TAF8 and SPT7L in human TFTC preparations. Subsequently, however, we demonstrated that TAF8 was not
a stable component of TFTC, but that it is present in a small TAF complex (SMAT), containing TAF8, TAF10 and SPT7L, that co-
purified with TFTC. Thus, TAF8 is a subunit of both TFIID and SMAT. The latter has to be involved in a pathway of complex
formation distinct from the other known TAF complexes, since these three histone fold (HF)-containing proteins (TAF8, TAF10
and SPT7L) can never be found together either in TFIID or in STAGA/TFTC HAT complexes. Here we show that TAF8 is
absolutely necessary for the integration of TAF10 in a higher order TFIID core complex containing seven TAFs. TAF8 forms
a heterodimer with TAF10 through its HF and proline rich domains, and also interacts with SPT7L through its C-terminal region,
and the three proteins form a complex in vitro and in vivo. Thus, the TAF8-TAF10 and TAF10-SPT7L HF pairs, and also the SMAT
complex, seem to be important regulators of the composition of different TFIID and/or STAGA/TFTC complexes in the nucleus
and consequently may play a role in gene regulation.
Citation: Deme ´ny MA, Soutoglou E, Nagy Z, Scheer E, Ja `nosha `zi A, et al (2007) Identification of a Small TAF Complex and Its Role in the Assembly of
TAF-Containing Complexes. PLoS ONE 2(3): e316. doi:10.1371/journal.pone.0000316
INTRODUCTION
Transcription initiation of protein-coding genes by RNA poly-
merase II (Pol II) requires the ordered assembly of general
transcription factors (GTFs) at the minimal promoter of these
genes to form a functional preinitiation complex (PIC). Tran-
scription factor TFIID, comprised of the TATA binding protein
(TBP) and series of TBP-associated factors (TAFs) [1,2,3], is the
GTF that by recognizing the promoter sequences allows the site
specific assembly of the PIC. We have previously shown that in
HeLa cells different human TFIID complexes, containing or
lacking TAF10, exist, which exhibit functionally distinct properties
[4,5]. TAFs are not only integral components of TFIID, but are
also found in the yeast Spt-Ada-Gcn5 acetylase (SAGA) coacti-
vator complex [6]. Likewise in mammalian cells, TAFs are shared
between TFIID and three very closely related multiprotein
complexes, which we refer to as STAGA/TFTC-like complexes:
the TBP-free TAF-containing complex (TFTC), the p300/CBP
associated factor (PCAF) complex, the GCN5 complex and the
SPT3-TAF9-GCN5 containing complex (STAGA) [7,8,9]. All of
these complexes contain homologues of the yeast histone acetyl
transferase (HAT) GCN5, as well as a subset of SPT and ADA
proteins, the 400 kDa protein TRRAP, and a number of TAFs
(shared TAFs) also found in TFIID. TFTC is structurally similar to
TFIID [10,11], and although devoid of TBP, it is capable of
functionally replacing TFIID at both TATA-containing and
TATA-less promoters in vitro [7].
Electron microscopy, yeast genetics, X-ray crystallography and
biochemical experiments have shown that histone fold (HF) motifs
mediate many of the subunit interactions within the yeast TFIID
and SAGA complexes [12]. In addition, HF-containing TAFs play
also roles in promoter recognition and exert coactivator function
by interacting and possibly recruiting components of the
preinitiation complex [12,13,14,15]. At present five HF-containing
TAF pairs have been described or suggested to exist in TFIID:
TAF6-TAF9, TAF4-TAF12, TAF11-13, TAF8-TAF10 and
TAF3-TAF10 [13,16,17,18,19]. The mapping of histone-like
TAFs in yeast TFIID revealed that these TAF pairs are organized
in three distinct lobes within TFIID [20] and not in a single
octamer-like structure as previously suggested. Similarly, in SAGA
the existence of three putative HF domain-containing heterodimer
pairs has been suggested: TAF6-TAF9, TAF10-Spt7p and
TAF12-Ada1 [12] and refs. therein). The spatial distribution of
TAF5, TAF6 and TAF10 was found similar in SAGA and TFIID
and was used as the basis of alignment of the two complexes
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TFIID, which could be involved in DNA binding, is similar to the
cleft formed by domains II, III, and IV of SAGA. The location of
TAF5 together with the HF domain-containing proteins in both
complexes suggests that similarly to TFIID, the WD-40 repeat-
containing TAF5 protein that forms the structural backbone of the
complex connects the HF-heterodimer pairs within SAGA
complexes. Recently, we have shown that the human TAF10
can form three HF pairs with TAF3, TAF8, or SPT7L, which is
the human orthologue of yeast Spt7p, also called STAF65c [15]
[22].
Drosophila Prodos (PDS) is a protein essential for cell viability
that comprises a HF, which selectively heterodimerises with
dmTAF10b, but not with dmTAF10 [23]. Consequently it was
proposed that PDS is a Drosophila TFIID component [23] and has
been named dmTAF8 [3]. Recently the human homologue of
TAF8 (TAFII43) was also described as an integral component of
TFIID [13]. Both PDS and human TAF8 are orthologues of
mouse Taube Nuss (TBN), which is essential for early embryonic
developmental events [24]. Interestingly, TBN-/- (TAF8-/-) and
TAF10-/- mice have the same phenotype showing that the lack of
either mmTAF8 or mmTAF10 leads to dramatic, but selective,
cell death in the inner cell mass [24,25]. These knock out results
further underline the possibility that these two mammalian
proteins interact in vivo and have similar or related roles in the
respective TAF-containing complexes.
Recently we have shown that exogenously expressed TAF10
remains mainly cytoplasmic and leptomycin B does not affect this
localisation [15]. By using fluorescent fusion proteins, we showed
that TAF10 needs one of its three HF-containing interaction
partners (TAF3, TAF8 or SPT7L) to be transported into the
nucleus. When the nuclear localisation signals of either TAF8 or
SPT7L are mutated, TAF10 remains cytoplasmic, but a heterol-
ogous NLS can drive TAF10 into the nucleus. Moreover, TAF10
binding to importin b in vitro was dependent on the co-expression
of either TAF8 or TAF3, but not SPT7L [15]. These data suggest
that a complex network of regulated cytoplasmic associations may
exist among these factors, which is important for the assembly of
different TFIID and TFTC-type complexes in the nucleus.
Much attention has been focused on the exact subunit
composition of multiprotein coregulator complexes with relatively
little attention paid to how these complexes are assembled and
disassembled in the cell, a theme that appears to involve more
dynamism and versatility than previously imagined. In order to
further investigate how TAF-interactions regulate the formation of
TFIID and TFTC/STAGA, we performed additional proteomic
and biochemical analyses to identify in which complexes TAF8
and SPT7L are found. Here we demonstrate that human TAF8
can interact in vitro and in vivo with TAF10 through its HF and with
SPT7L through its C-terminal region. Moreover, we show that
TAF8 is absolutely required for the integration of TAF10 in
a higher order TAF complex containing seven TAFs. Interestingly,
we discovered that TAF8 is not a stable component of TFTC/
STAGA complexes, but is present in a novel small TAF complex
(SMAT), containing TAF8, TAF10 and SPT7L. The fact that
TAF8, TAF10 and SPT7L can never be found together either in
TFIID or in TFTC/STAGA-type complexes suggests that SMAT
has a separate role in the regulation of transcription. As the
expression of TAF8 may regulate the nuclear localization of other
TAFs and/or TFTC subunits, as well as specific cell differentiation
processes, the SMAT complex may be an important regulator of
the composition of different TFIID or TFTC-type complexes in
the nucleus and/or cell differentiation processes.
RESULTS
Identification of human TAF8 and SPT7L in TFTC
preparations
In order to identify new TFTC subunits [7], two protein species
migrating around 45 and 65 kDa were excised from a 10% SDS-
PAGE and analysed by either microsequencing (45 kDa band) or
by MALDI mass spectrometry (65 kDa band). The analysis of the
protein species migrating around 45 kDa by Edmann degradation
and microsequencing resulted in the following tryptic peptide
sequences: (R)EPVSDYQVLR, (K)TGETQSL, (K)DDVS-
TFPLIAAR, (K)ENTSVLQQNPSL. Database searches indicated
that these peptides all originated from human TAF8. The MALDI
mass spectrometry analysis of the 65 kDa protein species identified
5 peptides: (R)YWGEIPISSSQTNR, (R)SSFDLLPR, (R)N-LI-
TAQAQNQQQTEGVK, (K)NPNAPFQIR, (R)HSDPESDFYR
(Figure S1). They all corresponded to a 414 amino acid human
protein (O94864 and AAG47636; coverage: 14%; average mass
accuracy: 30 ppm) that has an overall sequence similarity of 46%
to the C-terminal half of yeast Spt7p (Figure S1), a component of
the yeast SAGA complex. The identified human protein contains
a putative HF motif similar to that of ySpt7p. Thus, following the
yeast SAGA subunit nomenclature, we called this human protein
Suppressor of Ty 7-like (hereafter SPT7L) [15]. Note however,
that human SPT7L lacks the bromodomain present in yeast Spt7p
(Figure S1). SPT7L has already been identified as a tumour-
rejection antigen in lung adenocarcinoma (named ART1/P17
[26]) and, in good agreement with our results, described also as
a subunit of the human STAGA complex (called STAF65c [22]).
To verify the presence of TAF8 and SPT7L in TFTC
preparations, we raised anti-peptide rabbit polyclonal and mouse
monoclonal antibodies (mAbs) against TAF8 and hSPT7L (see
Materials and Methods). These antibodies recognized both
recombinant and endogenous TAF8 and SPT7L proteins,
respectively and were then used to verify the presence of TAF8
and SPT7L in purified human TFTC and TFIID preparations by
Western blot analysis. TAF8 was present in TFTC, and also in
TFIID (Fig. 1A). In agreement with previous data [22], SPT7L
was present in TFTC, but not in highly purified TFIID
preparations (Fig. 1A). These results suggest that human TAF8
is a component of both TFIID and TFTC (see also below), while
SPT7L is a TFTC specific subunit.
In vitro TAF8 interacts with several TAFs, but only
with SPT7L among the TFTC/STAGA specific
subunits
First, we wanted to determine with which TFIID or TFTC
subunits TAF8 would interact. To this end, TAF8 was co-
expressed with either one of the human TAFs or TBP (two left
columns in Fig. 1B), or specific human TFTC/STAGA subunits
(right column in Fig. 1B) using a baculovirus expression system in
Sf9 insect cells [27,28]. Each factor was also expressed alone as
a control. From these cells total protein extracts were made,
proteins were immunoprecipated (IPed) with an anti-TAF8 mAb
(2TAU 2B8), and bead-bound proteins were analysed by Western
blot. This experiment showed that in vitro TAF8 could interact
with several HF-containing TAFs (TAF6, TAF10 and TAF13),
with the WD40 containing TAF5, and TBP (Fig. 1B, two left
columns). Among the tested TFTC specific subunits, only SPT7L
interacted stably with TAF8 (Fig. 1B, right column and see
Fig. 1C). These proteins were not IPed from Sf9 extracts where
they were expressed individually without TAF8 (Fig. 1B).
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confirmed in several different species [13,15,18,23] we wanted to
fine map the minimal regions of either TAF8 or TAF10 that are
sufficient for this interaction. To this end TAF8 and its truncated
mutants were expressed in E. coli as GST fusion proteins, bound to
glutathione sepharose beads, and used for pull-down experiments
with baculovirus overexpressed TAF10 (Fig. 2A). TAF10 is weakly
binding to the formerly defined HF domain of TAF8 (GST-TAF8
24-104; Fig. 2A lane 5), however this binding is significantly
enhanced when the proline rich domain of TAF8 is present in the
mutants (compare lane 4 with 5). Note that the C-terminal half of
TAF8 lacking the HF, but containing the proline rich domain does
not bind TAF10 (lane 6). When mapping the minimal interaction
domain of TAF10 with TAF8 in a similar GST pull-down
experiment we found that amino acids 100 to 218 of TAF10,
containing its evolutionary conserved region including the putative
HF, are sufficient to interact with TAF8 (Fig. 2B). These results
demonstrate that TAF8 and TAF10 interact through their HF
domains, and this interaction is strengthened by additional
contacts or potential conformational changes mediated by the
proline rich domain of TAF8.
Surprisingly, baculovirus expressed TAF8 interacts very strong-
ly with SPT7L (Fig. 2C). Since this is the only TFTC specific
subunit that interacts with TAF8 among the tested subunits, and
because SPT7L contains also a putative HF, we mapped the
domain of TAF8 that is involved in the interaction with SPT7L.
To this end the same TAF8 mutants were used that were described
above (Fig. 2A lowest WB panel). Interestingly, the TAF8 HF and
proline rich domains do not seem to be involved in the interaction
between the GST-TAF8 mutants and the baculovirus expressed
SPT7L (lanes 4 and 5). Contrary to our original expectation, the
region of TAF8 that interacts with SPT7L is at the C-terminal end
between amino acids 194 and 308 (Fig. 2A lane 6). These results
suggest that TAF10 and SPT7L do not bind to the same region of
TAF8.
TAF8 and SPT7L interact in the cell
To verify the surprising novel interaction found between TAF8 and
SPT7L in vivo, we expressed a truncated form of TAF8 that lacks its
C terminal nuclear localization signal (NLS). We then asked the
question whether the interaction between SPT7L and TAF8 would
be maintained and thus SPT7L would take the TAF8 mutant into
the nucleus (Fig. 3A). The cells were first transfected with a construct
expressing a truncated version of TAF8(1-294) lacking the NLS of
TAF8 as a CFP fusion protein individually (Fig. 3A). When the
cellular localisation of this fusion protein was analysed, as expected,
the TAF8(1-294) mutant localised exclusively to the cytoplasm
(Fig. 3A). Next, we co-expressed the CFP-TAF8(1-294) mutant with
YFP-SPT7L in HeLa cells and tested their localisation. In the pres-
ence of SPT7L the TAF8(1-294) mutant became nuclear (Fig. 3A),
indicating that the two proteins interact in the cell.
Next, we aimed to further analyse the TAF8/TAF10 and
TAF8/SPT7L interactions in living cells and compare them to
that of a previously characterised TAF pair. To this end, we
measured FRET by the sensitized emission method in living cells.
HeLa cells were transfected with constructs expressing the YFP/
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Figure 1. TAF8 is present in both TFIID and TFTC preparations while SPT7L is associated with TFTC. (A) TFIID and TFTC complexes were purified
[7], separated by SDS-PAGE and the presence of different subunits were analysed by Western blot using the indicated antibodies. (B) TAFs, TBP (left
panels) and certain TFTC subunits (right panels) were individually expressed (In factor) or coexpressed with TAF8 (In factor+TAF8) in Sf9 cells as
indicated and WCEs were made. TAF8-containing complexes were immunopurified (IPed) with an anti-TAF8 mAb (2TAU 2B8). Protein expression in
the input fractions and TAF8-bound proteins were analysed by western blot with the indicated antibodies. In each experiment, the expression and
the IP efficiency of TAF8 was the same as shown in a single representative experiment (lower panel).
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SPT7L pairs, as well as the TAF6/TA9 HF pair as a positive
control. Mean FRET efficiencies were measured in the nucleus of
25–30 individual cells for each combination. When measuring
FRET with the control CFP/YFP pair, where the two fluorescent
proteins are supposed to interact only randomly, we obtained
FRET efficiencies varying between 0 and 4% in all cells, with an
average of 1.03% (Fig. 3B). Thus, in all the other transfections we
have only considered cells with values above the 5% threshold as
positives. Using these criteria, both the TAF8/TAF10 and TAF8/
SPT7L interactions resulted in similar FRET efficiencies, at
around 16–17% (Fig. 3B). The positive control TAF6/TAF9 HF
pair gave 27.1% FRET efficiency (Fig. 3B). The above data
indicate that TAF8-TAF10 and TAF8-SPT7L pairs form in vivo.
TAF8 is absolutely required for the incorporation of
TAF10 into a higher order TAF complex
Over the past years our efforts to build complete or recombinant
human TFIID complexes containing TAF10, using the baculo-
virus overexpression system, have been without any success. When
TAF10 was overexpressed with all the known TFIID subunits,
except for TAF8, TAF10 was unable to interact with any of the
other TAFs or TBP (Table 1 line 1; and data not shown).
However, when TAF8 was also included in the coinfection where
in total 13 subunits of the TFIID complex were expressed; we were
able to coprecipitate TAF10 with six other TAFs (TAF4, -5, -6, -8,
-9, -10 and –12) containing three HF pairs (TAF4–12, TAF6–9,
and TAF8–10) and the WD40 repeat-containing TAF5 (Table 1
see second line). When only these seven TAFs were coexpressed
they, indeed, formed a single complex (Figure 4B and C lanes 2;
and Table 1 fourth line), as demonstrated also by size fractionation
of the immunopurified material [28]. Interestingly however, when
any of the seven TAFs was left out from the co-infection, this
recombinant seven TAF-containing complex did not form and
TAF10 interacted only with TAF8 (Fig. 4 and Table 1 compare
lines 3–4). In good agreement with the high specificity interactions
occurring in this seven TAF complex, the TAF8-TAF10 HF pair
did not interact with any other HF-containing TAF pair
individually or in combination (Table 1, lines 5–8). Moreover,
when these individual TAF pairs were coexpressed with the
WD40-containing TAF5, no interactions with the TAF8–TAF10
pair were detected (Table 1, lines 9–13). Similarly, no interactions
between TAF8–TAF10 HF pair and the other factors could be
detected when TBP, TAF1, TAF2 and TAF7 were co-expressed
with the above tested TAF combinations (see Table 1, lines 14–
24). These experiments together demonstrate that TAF8 is
necessary for the incorporation of TAF10 in a higher-order seven
TAF complex and that the simultaneous incorporation of all of
these factors (TAF4, -5, -6, -8, -9, and -10) is absolutely required to
form this stable recombinant TFIID subcomplex.
Moreover, the comparison of the pair wise interaction profile
obtained between TAF8 and many of its potential partners (Fig. 1B)
with that obtained between the TAF8-TAF10 HF pair and a large
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interactions within the TFIID complex amongst TAFs or TAF pairs
become more and more specific when more interaction partners are
coexpressed together. These simultaneous, highly specific multiple
interactions seem to eliminate weaker, promiscuous interactions [29]
amongst TAFs or HF-containing TAF pairs.
TAF8 is not a subunit of TFTC/STAGA type
complexes, but is present in TFIID and a novel TAF8-
, TAF10- and SPT7L-containing complex
To further characterize the association of TAF8 with TFTC/
STAGA complexes we first immunoprecipitated TFTC/STAGA
complexes with an antibody raised against ATXN7, a recently
characterized subunit of TFTC/STAGA [30,31], and looked for
the presence TAF8 in these complexes by western blot analysis
(Fig. 5A lane 3). Surprisingly, and in contradiction with the initial
mass spectrometry data, no TAF8 could be detected in these
ATXN7-containing TFTC/STAGA complexes. However, we
detected TRRAP, GCN5, TAF10 by western blot (lane 3) and
also ATXN7, TAF5L, TAF6L, ADA1 (STAF42) and SPT7L by
mass spectrometry (data not shown). To further verify this
surprising observation we carried out a reciprocal anti-TAF8 IP
using the 2TAU 2B8 mAb and tested the presence of TFTC/
STAGA or TFIID subunits in this immunopurified fraction that
contains only TAF8-associated proteins. By western blot analysis
we detected in this fraction TFIID subunits such as TAF5, TAF6,
TAF8, TAF10 and TBP, but no TRRAP and GCN5, which are
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Figure 3. TAF8 and SPT7L interact in vivo (A) The nuclear localization of TAF8 lacking the NLS [TAF8(1-294] depends on its in vivo interaction with
SPT7L. HeLa cells were co-transfected with the indicated CFP- and YFP-containing expression vectors and localization of the expressed proteins were
visualised by fluorescence microscopy. The images shown in each panel are representative of all the transfected cells. (B) Sensitized emission of YFP
fusion proteins due to FRET was measured in two different experiments in the nucleus of 25 individual HeLa cells transfected with the indicated
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horizontal line in each graph), and for the other pairs only values above this level were averaged. The average value of the negative control is 1.03%.
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PLoS ONE | www.plosone.org 6 March 2007 | Issue 3 | e316specific TFTC/STAGA components (Fig. 5B lane 3). This finding
seemed to be in agreement with the results of the above ATXN7
IP and with those of Guermah et al. [13] showing that TAF8 is not
a STAGA component. Unexpectedly however, we detected
SPT7L, a TFTC/STAGA component, in the TAF8 IP. One
way to explain the presence of SPT7L alone in the TAF8 IP,
without other TFTC components, is that TAF8 in vivo forms also
a complex with SPT7L (as we have shown above by different
interaction experiments) and that this complex is not present in
TFTC. To verify this hypothesis we depleted TBP-containing
(TFIID) complexes from the immunoprurified TAF8-containing
complexes by using an antibody raised against TBP. The depletion
of TFIID from this fraction (anti-TBP IP SN2 in the scheme of
Fig. 5B) was complete, since we could not detect TAF5, TAF6 and
TBP in this SN2 fraction, however we could still detect SPT7L,
TAF8 and TAF10 (Fig. 5B lane 4). To confirm that the three
proteins are present in the same complex, we performed a two-step
immunoprecipitation from HeLa NE. We first purified the TAF8-
containing complexes and then reprecipitated TAF10 from the
eluate of the first IP with an anti TAF10 mAb (Fig. 5C). TAF8,
TAF10, SPT7L could be co-precipitated in the second IP, showing
that they are present together in a complex. Mass spectrometry
analysis of the SN2 fraction in Fig. 5B did not reveal the presence
of additional known TFIID or TFTC subunits. These findings
suggest that in the cells a protein complex exists containing
SPT7L, TAF8 and TAF10, but no other TFIID or TFTC specific
subunits. The existence of such a SPT7L-, TAF8- and TAF10-
containing complex that is different from all the previously
described TAF-containing complexes, also explains why we have
originally identified TAF8 in our TFTC preparation (see
Discussion).
The TAF8-, TAF10- and SPT7L-containing complex
can also be formed in vitro
Since TAF8, TAF10 and SPT7L could be found in a complex
together in endogenous HeLa nuclear extracts and since TAF8
interacts with both TAF10 and SPT7L, [15] we verified whether
these three proteins can form a trimeric complex in vitro. Flag-
SPT7L TAF8- and TAF10- were coexpressed in Sf9 cells and
purified by a double IP, either with an anti-FLAG IP followed by
an anti-TAF10 IP (Fig. 5D) or vice versa, with an anti-TAF10 IP
followed by an anti-FLAG IP (data not shown). TAF8-, TAF10-
and SPT7L could be co-immunoprecipitated in both cases (Fig. 5D
lane 3, and data not shown), confirming that these three proteins
can form a recombinant complex.
Since all the three subunits of this small TAF8-, TAF10- and
SPT7L-containing complex (SMAT) are never present at the same
time either in TFIID or in STAGA, we hypothetised that SMAT
could be a storage complex for these factors, which upon getting
incorporated into the appropriate complex would inflict on
whether a TFIID or STAGA/TFTC is to be assembled. To test
this hypothesis, we coexpressed all the described subunits of the
seven TAF complex with SPT7L or we replaced TAF8 in the
seven TAF complex with SPT7L. When SPT7L was coexpressed
with the subunits of the seven TAF complex, we could still
immunopurify with an anti-TAF10 mAb the seven TAF complex,
but SPT7L did not incorporate in this complex (Table 1 line 25).
TAF10
IgG H
TAF4
TAF9
TAF6
TAF8
TAF5
IgG L
TAF10
TAF4
TAF9
TAF6
TAF8
TAF5
TAF12
TAF10
TAF4
TAF6
TAF8
TAF5
TAF12
AB C
-TAF10
4+5+6+8+9+10+12
-TAF4
-TAF12
-TAF6
-TAF9
-TAF5
12 34 5 67 1 2 3 4 5 67
12 34567
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Figure 4. The TAF8-TAF10 HF pair incorporates into a higher order TFIID subcomplex only if another five TAFs are simultaneously present. (A)
Either seven TAFs (TAF4, -5, -6, -8, -9, -10 and -12) or only six of them (each time only the omitted TAF is indicated compared to the seven-TAF
complex) were coexpressed in Sf9 cells and WCEs made. Protein expression in the WCEs was verified by western blot analysis (WB). Note that in the
seven-TAF complex each TAF is indicated with only its corresponding number according to the TAF nomenclature [3]. (B–C) TAF10-containing
complexes were purified from the WCEs with an anti-TAF10 mAb (1H8). Bound complexes were eluted by peptide competition and analysed either
by western blot (WB) with the indicated antibodies (B) or by silver nitrate staining (Silver) (C).
doi:10.1371/journal.pone.0000316.g004
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PLoS ONE | www.plosone.org 7 March 2007 | Issue 3 | e316Moreover, when TAF8 was left out from the seven TAF complex
and replaced by SPT7L, TAF10 interacted only with SPT7L, but
the other TFIID TAFs did not form a complex with the TAF10-
SPT7L heterodimer (Table 1 line 26). Together these data
indicate that when all the subunits of a potential TFIID core
complex are present, SPT7L cannot turn the formation of the
TFIID core into a STAGA/TFTC core. Conversely, when the
formation of a TFTC core is initiated by the formation of
a TAF10-SPT7L HF pair, the TFIID core cannot assemble (see
also below and Discussion).
The novel TAF8-, TAF10- and SPT7L-containing
complex has a size of 300–400 kDa
To determine the size of the SMAT complex, we first
immunopurified all the TAF10-containing complexes from HeLa
NE by an anti-TAF10 IP and the eluted material was immediately
injected on a Superose 6 size exclusion chromatography column.
Testing the elution profile of TAF8-, TAF10- and SPT7L we
observed that these proteins eluted mainly in two peaks: one
between 1 and 2 MDa and a second around 300–400 kDa
A
Input NE
α-TAF10 IP
α-ATXN7 IP
α-TBP IP
TRRAP
GCN5
TAF8
TBP
TAF10
123 4
B
SPT7L
TAF8
TRRAP
TAF10
TAF5
TAF6
GCN5
 
α-TAF10 IP
anti-TBP IP Bound (TFIID)
anti-TAF8 IP E1
anti-TBP IP SN2
14 3 2
C
SPT7L
TAF8
TAF10
123
HeLa NE 
SN
anti-TAF8 IP
Elution
E1
anti-TAF10 IP
Bound
(SMAT)
SN
D
Input 
anti-Flag IP E1
Flag-SPT7L
TAF8
TAF10
123
anti-TAF10 IP E2
Sf9 Extract
SN
anti-Flag IP
Elution
E1
anti-TAF10 IP
Elution
E2
SN
HeLa NE
SN1
anti-TAF8 IP
Elution
E1
anti-TBP IP
Bound
(TFIID)
SN2
TBP
anti-TAF8 IP E1
anti-TAF10 IP Bound (SMAT)
- control
IgG L
Figure 5. TAF8 is not a subunit of TFTC/STAGA type complexes, but is present in TFIID and a novel TAF8-, TAF10- and SPT7L-containing complex
that can also be formed in vitro. (A) The indicated transcription factors were immunoprecipitated using specific mAbs (1H8 anti-TAF10; 2A10 anti-
ATXN7 and 2C1 anti-TBP) from HeLa cell nuclear extract (NE) and eluted by an excess of peptides against which the mAbs were raised. Eluted protein
complexes were separated by SDS-PAGE and analysed by western blot with the indicated antibodies. (B) TAF8-containing protein complexes were
purified from HeLa NE according to the scheme shown on the left of the panel. The eluate obtained after the first anti-TAF8 IP using the 2TAU 2B8
mAb (anti-TAF8 IP E1; lane 3) and the supernatant obtained after the TAF8-containing complexes were depleted in TFIID using the anti-TBP 2C1 mAb
(SN2; lane 4). They were separated along with complexes obtained after an anti-TAF10 IP (TFIID and TFTC together; lane 1) or with a highly purified
TFIID fraction (lane 2) on SDS-PAGE and analysed with the indicated antibodies by western blot. (C) TAF8 containing complexes were purified from
HeLa NE according to the scheme on the left of the panel. TAF10-containing complexes were re-precipitated from the eluate obtained after the first
anti-TAF8 IP (E1, lane 1) extensively washed and loaded after boiling the beads (lane 2) with loading buffer on a SDS-PAGE. The migration of the
antibody alone (-control) is shown in lane 3. Proteins were analyzed with the indicated antibodies by western blot. (D) TAF8, TAF10 and Flag-SPT7L
were co-expressed in Sf9 cells. WCEs were made and proteins were subjected to two successive immunoprecipitations and elutions by peptide
competition according to the schemes shown on the left of the panel. Input and eluted protein complexes were separated by SDS-PAGE and
analysed with the indicated antibodies by western blot.
doi:10.1371/journal.pone.0000316.g005
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PLoS ONE | www.plosone.org 8 March 2007 | Issue 3 | e316(Fig. 6A). The broad elution profile of TAF10 suggests that this
protein as well as proteins associated with it is present in several
different complexes in human HeLa cells.
To further verify the presence of these different smaller TAF-
containing complexes in HeLa cell extracts, we fractionated
a crude HeLa cell nuclear extract (NE) on the same Superose 6 gel
filtration column (Fig. 6B). The two peaks obtained for the largest
subunit of RNA Pol II (RPB1) correspond to the previously
described holo-polymerase (about 2 MDa) and core polymerase
complexes (650 kDa) [32], as well as the two peaks of TBP
correspond to the previously described TBP-containing complexes
[33]. The correct separation of these complexes confirmed that
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Figure 6. The TAF8-, TAF10- and SPT7L-containing complex has a size of about 300–350 kDa and may exist in vivo in crude nuclear extracts.
Immunupurified and eluted TAF10-containing complexes (TAF10 IP) (A), or HeLa nuclear extract (NE) (B) (50 ml) were injected on a Superose 6 size
exclusion chromatography column using the SMART FPLC system (Pharmacia) and separated. Portions of the input (in; 5 ml) and every fraction from 7
to 38 (20 ml) were analysed by western blot (as indicated). Fraction numbers are shown under each lane and the elution profile of known molecular
mass markers is indicated above the panels. To detect the non-phosphorylated form of SPT7L, 20 ml from each fraction was first phosphatase treated
for 30 min at 37uC, then separated by SDS-PAGE and analyzed by western blot with the anti-SPT7L mAb (panel SPT7L-PPase). (C) Baculovirus
expressed SPT7L in WCE (lane 2) and purified TFTC (lane 4) were treated with phosphatase (PPase) for 30 min at 37uC, separated on SDS-PAGE and
analysed by western blot with the anti-SPT7L mAb (15) (upper panel), and an anti-TAF10 mAb (lower panel). The corresponding mock treated
fractions are shown in lanes 1 and 3, respectively.
doi:10.1371/journal.pone.0000316.g006
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PLoS ONE | www.plosone.org 9 March 2007 | Issue 3 | e316our NE contained intact complexes. Interestingly, while TAF4,
TAF5 and TAF6 eluted from the column as a single peak in the 1–
2 MDa range, TAF8 and TAF10 were detected in at least two
peaks eluting from the column in a molecular range of 1–2 MDa
and about 400–500 kDa. Surprisingly, SPT7L was detected in
only a peak around 450–500 kDa. Our anti-SPT7L mAb
recognizes mainly the phoshatase treated form of recombinant
SPT7L in western blot analysis (Fig. 6C lanes 1 and 2) suggesting
that one or several of the amino acids in the SPT7L epitope
(QSPDDSDSSYGSHSTDSLM) are phosphorylated. Endogenous
SPT7L is also phosphorylated in the TFTC complex because
SPT7L can be better detected following phosphatase treatment of
the complex by western blot analysis (Fig. 6C, compare lane 3 and
4). To verify whether the lack of SPT7L detection in the Superose
6 fractions containing the higher molecular weight complexes was
due to the phophorylation of SPT7L, each fraction was
phosphatase treated and then analysed again by western blot.
When comparing the two series of blots (SPT7L and SPT7L-
PPase panels in Fig. 6B) it became clear that SPT7L is present also
in higher molecular weight complexes as expected, but that the
majority of SPT7L peaks around 450–500 kDa. These data
together suggest that the NE fractions around 400–500 kDa
contain the above-described TAF8-, TAF10- and SPT7L-contain-
ing complex (Fig. 6B fractions 24–27). Interestingly, the elution
profile of each tested factor is shifted towards higher molecular
weights in the fractionation of crude NE when compared to the
separation of the IP-ed complexes (compare panel A and B in
Fig. 6). This may be explained by the presence of additional
loosely associated proteins in the complexes (i.e. chaperones and or
transcription activators) found in the crude NE, which proteins,
due to the stringent washes during the immunopurification
(500 mM KCl and 0.1% NP40) could dissociate. These data
together demonstrate the existence of a TAF8-, TAF10- and
SPT7L-containing SMAT complex in HeLa cells.
DISCUSSION
TAF8 is not a STAGA/TFTC component
The main finding of this study is the discovery of a novel TAF-
containing complex, that we call SMAT. SMAT is composed of
three HF-containing factors, TAF8, TAF10, SPT7L, and
potentially as yet unidentified proteins. Despite that we identified
TAF8 from our original TFTC preparations, using TFTC/
STAGA specific antibodies we show here that TAF8 was not
a component of the large 2 MDa TFTC/STAGA complex, but it
was present in a smaller complex that copurified with the TFTC
preparation. As the TFTC fraction was the supernatant of a second
TBP IP step [7] it remained possible that this TFTC preparation
may contain several different TAF10-containing complexes. The
gel filtration of these endogenous complexes, as well as the size
separation of the crude NE, on a Superose 6 column clearly shows
that in HeLa cells more TAF10-containing complexes exist than
originally expected. Our results presented here indicate that
TFTC is a mixture of STAGA, SMAT and possibly other TAF10-
containing complexes. Moreover, it is important to realize that
SMAT cannot be a break down product of either TFIID, or
STAGA because TFIID does not contain SPT7L and because
STAGA does not contain TAF8 (13 and this study).
What is the role of the novel TAF8-, TAF10-, SPT7L-
containing complex?
One possible role of SMAT could be that it controls the nuclear
equilibrium between TFIID and TFTC/STAGA-type complexes.
In yeast TFIID function seems to predominate approximately
90% of tested genes and SAGA function is important at
approximately 10% of the yeast genome. TFIID-dependent genes
seem to be more ubiquitously expressed, SAGA-dependent ones
on the other hand, seem to be largely stress induced [34]. Thus, it
is conceivable that a TAF8-, TAF10-, SPT7L-containing complex
by releasing or sequestering TAF8 and/or SPT7L may regulate
the quick assembly or disassembly of complete TFIID or TFTC/
STAGA-type complexes in response to stress or once the stress is
over.
The fact that the TAF8-TAF10 HF-containing heterodimer
does not interact with any other TFIID subunit individually or in
combination to form a partial or complete TFIID complex
(Table 1), unless TAF4, TAF5, TAF6, TAF9 and TAF12 are
simultaneously present (Fig. 4), suggests a high degree of regulation
in the assembly of the TAF-containing complexes. Wright et al.
(2006) recently suggested the existence of a stable Drosophila core
TFIID subcomplex, consisting of TAF4, TAF5, TAF6, TAF9 and
TAF12 [35]. The formation of the stable seven-TAF complex is
consistent with the physiological existence of a TFIID core that,
according to our results, would also incorporate an additional HF
pair, the TAF8-TAF10 pair. As previously suggested [28] the
accretion of a core with either TFIID- or STAGA-specific subunits
would commit the assembly process into the formation of one
complex or the other. We show here that, in addition to SMAT,
the TAF8-TAF10 pair is only present in TFIID, while the TAF10-
SPT7L pair is exclusively present in STAGA. Moreover, our
reconstitution experiments suggest that the formation of one of
these dimers is one of those points, where the assembly of TFIID
or STAGA may bifurcate. Our observations suggest that the
formation of SMAT, in which the TAF8-TAF10 and TAF10-
SPT7L HF pairs are connected by a TAF8-SPT7L interaction,
would block the incorporation of the TAF8-TAF10 or TAF10-
SPT7L hetrodimers in TFIID or in STAGA type complexes,
respectively. Thus, the expression levels of these factors in the cell
and especially their quantity in the nucleus may thus be crucial for
the formation of the respective complexes.
Moreover, it is possible that cellular signals induced by stress or
other stimuli induce a cascade of events that would posttransla-
tionally modify one or several components of the TAF8-, TAF10-,
SPT7L-containing complex, and this modification would then
release factors from this complex. In agreement with such a model,
SPT7L is phosphorylated in STAGA/TFTC, but not in SMAT.
Such modifications together with our previous observations that
TAF10 needs one of its three HF partners for entering into the
nucleus [15], may participate in the regulation of the assembly of
TFIID or TFTC/STAGA-type complexes and thus play a role in
the regulation of gene expression.
Alternatively, this TAF8-, TAF10-, SPT7L-containing complex
may also be independently recruited to promoters of specific genes
to regulate gene expression in addition to the already known TAF-
containing complexes. Such a scenario would possibly also explain
why the detectability of a given TAF versus others or TBP varies
between 1 and 100 arbitrary units at different active enhancers
and promoter regions when tested by chromatin immunoprecip-
itation [36,37]. Smaller TAF-containing complexes may be
recruited to promoters by activators, and known large TAF-
containing complexes (i.e. TFIID and TFTC/STAGA) would
only be assembled from such smaller complexes at promoters.
Alternatively, it is also conceivable that following activation of
transcription and PIC formation, TFIID and/or TFTC/STAGA
would be destabilised and they would leave the promoter as
smaller subcomplexes and not as a single big unit. In agreement
with these hypotheses it has been observed in vivo that two different
components of the TFTC/STAGA complex (TRRAP and GCN5)
A Novel Small TAF Complex
PLoS ONE | www.plosone.org 10 March 2007 | Issue 3 | e316arrive one after the other, and not together, to activated promoters
[38], and similarly that TRRAP and GCN5 stay longer at
promoters than other TFTC/STAGA subunits (i.e. TAF9 or
TAF10) following gene activation [39]. All these in vivo observa-
tions are in favour of a model, in which these large multiprotein
complexes are dynamically and probably constantly assembled
and dissociated in the cell nucleus depending on many different
cellular requirements.
The SMAT complex containing two HF pairs may form
a tetrameric, TAF10-TAF8-SPT7L-TAF10, or an octameric
structure, (TAF10-TAF8-SPT7L-TAF10)2, similar to that formed
by the four histones. The in vitro and in vivo interaction between
TAF8 and SPT7L, which does not involve the HF domain of
either of these proteins, explains how the TAF8-TAF10 and the
SPT7L-TAF10 HF pairs interact in SMAT. If organized in
a histone octamer like structure, the (two HF pairs)x2 would have
a molecular weight of about 350 kDa that would be close to what
we have determined by gel filtration (300–400 kDa).
The in vivo assembly of TAF-containing complexes
Our data also demonstrate that TAF-containing complexes are
not randomly formed, since no monomeric TAFs, or small
subcomplexes, containing for example TAF4, TAF5 or TAF6
were detected in HeLa NE (Fig. 6B). A cellular surveillance
mechanism by which the cell could distinguish between intact and
partial multiprotein complexes has not yet been described. Thus,
we believe that TAFs have a strong and intrinsic propensity for
association with other TFIID TAFs (and/or STAGA subunits in
the case of shared TAFs) and, once inside the nucleus (or even
before), a TAF would shortly be captured by other specific
subunits. This immediate recruitment would automatically gather
the TAFs or STAGA subunits into higher molecular weight
complexes (probably towards the formation of TFIID and TFTC/
STAGA complexes) and thus any TAF-containing complex
would, in the end, arise by a sort of self-assembly. This model is
in good agreement with the self-assembly of the seven-TAF
complex (Fig. 4 and Table 1) in which each subunit is needed to
form the complex. However, posttranslational modifications,
which occur in vivo, but are missing or different in our in vitro
system, may be responsible for lack of assembly of the complete
TFIID (Table 1, line 2). Alternatively, other mechanisms, such as
energy dependent chaperone activities may be required for the
completion of a seven-TAF-like subcomplex into TFIID.
Here we describe a novel TAF-containing complex and
hypothesizehowHF-containingTAFpairscanregulatethetopology
and possibly the local assembly of the different TAF-containing
complexes in which they are incorporated. Thus, this study suggests
that possibly more TAF-containing complexes exist in the cells than
originally described. Whether such complexes exist for most of the
known histone-fold containing TAF pairs during cellular differen-
tiation or metazoan development remains to be answered.
MATERIALS AND METHODS
Plasmid constructions and cell transfections
The eukaryotic expression plasmids for TAF8, TAF10, and
SPT7L, the baculovirus expression vectors for TAF3, TAF4,
TAF5, TAF6, TAF8, TAF9, TAF10, TAF12, as well as for SPT7L
and the YFP and CFP vectors for TAF8, TAF10 and SPT7L have
been previously described in [4,15,27,28,40]. The full length
ATXN7 cDNA fused to a sequence encoding a FLAG epitope was
excised from the pc7NFL [30] and cloned in the pVL1393
baculovirus vector. The ADA1 cDNA was amplified from a HeLa
cDNA library using complementary oligonucleotides and then
cloned into the Nde I and Bgl II sites of the pSK277 baculovirus
expression vector. The mouse ADA3 cDNA was excised from the
pSG5-ADA3 vector [41] and cloned in the Nde I-Xho I sites of the
pSK277 baculovirus vector. The hGCN5 cDNA was excised from
the pCDNA3-GCN5 vector [42] and cloned inthe Nde I-Xba I sites
of the pSK277 baculovirus vector. The human SPT3 cDNA was
excised from the pGEX-4T2-SPT3 vector [43] and cloned in the
Nde I-Bam HI sites of the pSK277 baculovirus vector. The
prokaryotic expression vectors for TAF10 have been described in[4]
and for TAF8 they were constructed by PCR amplifying the mouse
coding sequenceand inserting itinto a pGEX-4T3 expression vector
between the Eco RI and the Xho I sites. Deletion mutants were
similarly generated by PCR and they were inserted into pGEX-2T
as Bgl II-Eco RI fragments at the Bam HI and Eco RI cleavage sites.
All constructs were verified by sequencing.
1,5610
5 HeLa cells were transfected by using JetPEI (Poly-
plusTransfection, France) in 35mm plates and harvested at the
indicated time points after transfection. The Sf9 cell coinfections
were done as described in [27].
Immunisation and antibody production
The GTRSGSKQSTNPADNYHLA(C) peptide corresponding to
human TAF8 amino acids 14–32 was synthesised, coupled to
ovalbumin and used for generation of mouse monoclonal antibody
(2TAU 2B8) as described in [5]. All the other antibodies used have
been previously described in [7,15,25,28,30,44].
FRET measurements
For the fluorescence resonance energy transfer (FRET) measure-
ments a Leica TCS RS microscope was used that was equipped
with a 40 mW Ar laser. The images were acquired with 458 and
514 nm laser lines, which were adjusted to 10.5 and 2% maximal
laser power, respectively. Images were taken through a 6361.4-
numerical aperture oil immersion objective with 2–4 6 zoom.
Recording was done with two photomultiplier tubes (PMT1 and
PMT2). Tuneable split apertures defined the acquired bandwidth
as 468–501 nm for PMT1 and 523–600 nm for PMT2. We
recorded images in three configurations: i) excitation at 458 nm,
acquisition with PMT1 (=A); ii) excitation at 458nm, acquisition
with PMT2 (=B), and iii) excitation at 514 nm, acquisition with
PMT2 (=C). Images were acquired of single and double
transfected cells in all three configurations. FRET, indicating an
interaction between the CFP and YFP fusion proteins was
determined from the enhanced emission of the acceptor YFP in
the presence of the CFP-tagged partner. The a, b, and c constants
indicating spectral bleed thoroughs were determined and averaged
on a set of 20 cells with the Leica Confocal Software FRET
Application. FRET efficiency, defined as the fraction of emitted
acceptor energy originating from Fo ¨rster resonance energy
transfer from the donor was then calculated with the formula:
FRETefficiency (%)=[(B-b*A-(c-a*b)*C)/C]*100, where (a) is A/C in
cells transfected with only the acceptor expression vector; (b) is B/
A in cells transfected with only the donor expression vector; and (c)
is B/C in cells transfected with only the acceptor expression
vector. A, B and C are defined above.
Preparation of HeLa cell nuclear extract
HeLa cells were grown in suspension culture. 10
11 cells were
harvested by centrifugation and a nuclear extract was prepared
according to a modified protocol of Dignam [45]. Briefly, nuclei
were prepared by resuspending the pellets in 4 packed cell volume
(PCV) of 50 mM Tris-HCl, pH 7.9; 1 mM EDTA; 1 mM DTT
and proteinase inhibitors and opening the cells with a Dounce-
A Novel Small TAF Complex
PLoS ONE | www.plosone.org 11 March 2007 | Issue 3 | e316homogenizer. Nuclei were collected by centrifugation and lysed in
4 PCV of 50 mM Tris-HCl, pH 7.9; 25% glycerol; 500 mM
NaCl; 0.5 mM EDTA; 1 mM DTT and proteinase inhibitors by
powerful strokes. The lysate was centrifuged at 50000 g for
20minutes. The supernatant was filtered and proteins precipitating
in 30%(w/v) (NH4)2SO4 were pelleted. They were resuspended in
50 mM Tris-HCl, pH 7.9; 20% glycerol; 100 mM KCl; 5 mM
MgCl2; 1 mM DTT and dialysed against the same buffer.
Immunoprecipitation and Western blot analysis
Sf9 cell lysates were made as described in [28]. Proteins of Sf9 cell
lysates (from a 75 cm
2 Falcon flask) were immunoprecipitated (IP)
with 100 ml protein G-Sepharose (Pharmacia) and approximately
5 mg of the different antibodies (as indicated). Antibody-protein G
Sepharose bound protein complexes were washed three times with
IP buffer (25 mM Tris-HCl pH 7.9, 10% (v/v) glycerol, 0.1%
NP40, 0.5 mM DTT, 5 mM MgCl2) containing 0.5 M KCl and
twice with IP buffer containing 100 mM KCl. After washing,
proteins were eluted either by an excess of the corresponding
epitope peptide or protein-G-antibody-bound proteins were
directly boiled in SDS sample buffer and separated by SDS-
PAGE. Proteins were then both visualized by staining the gels with
Coomassie blue (or silver nitrate) or transferred to nitrocellulose
membrane, and probed with the indicated primary antibodies.
Chemiluminescence detection was performed according to
manufacturer’s instructions (Amersham).
Expression of proteins in bacteria and GST-pull
downs
Transformed BL21DE3 cells were grown at 37uCt o
O.D.600=0,6-0,8. They were induced with 0.1mM IPTG and
grown at 25uC for 45 minutes. The pelleted cells were lysed in
PBS-1% TritonX-100, 1 mM DTT, and proteinase inhibitors by
sonication. Soluble extracts (2 ml made from a 100 ml culture)
were incubated with 50–100 ml of pre-swollen glutathione
sepharose (Pharmacia) beads. The beads were extensively washed
with lysis buffer (see above) and then further incubated with Sf9
whole cell extracts, in which the indicated interaction partners
were overexpressed, for 2h at 4uC. Beads were again extensively
washed 3 times with IP buffer containing 500 mM KCl and then
twice with IP buffer containing 100 mM KCl. Bead-bound
proteins (10 ml) were directly boiled in SDS sample buffer and
separated by SDS-PAGE. Proteins were then detected by western
blot analysis (as above).
Mass spectrometry
TFTC subunits were separated on a 10% SDS-PAGE gel. Protein
bands were visualized by Coomassie G250 (Biorad) staining,
excised and in gel-digested with trypsin [46]. Peptides were either
microsequenced [47] or analysed by MALDI mass spectrometry.
For MALDI analysis peptide extracts (0.5 ml) were mixed with an
equal volume of saturated alpha-cyano-4 hydroxycinnamic acid
(LaserBio Labs) dissolved in 50% acetonitrile and applied to the
target. Mass measurements were carried out on a Bruker Reflex
IV MALDI-TOF spectrometer in the positive-ion reflector mode.
The acquisition mass range was 800–3000 Da with low mass gate
set at 700 Da. Internal calibration was performed using autolytic
trypsin peptides (MH
+ with m/z=842.51, 2211.11 and 2807.47).
Mono-isotopic peptide masses were assigned manually using the
Bruker X-TOF software. Database searches were performed using
Profound program (http://prowl.rockefeller.edu/) with the fol-
lowing parameters: database NCBI, proteins of human origin,
molecular mass between 20–100 kDa, trypsin digestion with one
missed cleavage allowed, cysteines modified by carbamidomethy-
lation, methionine oxidation and mass tolerance of 75 ppm.
Gel filtration chromatography
HeLa nuclear extract (,300 mg total protein in 50 ml) or
immunupurified and eluted TAF10-containing complexes were
injected on a Superose 6 PC3.2/30 size exclusion chromatography
column using the SMART FPLC system (Pharmacia) and
separated at a flow rate of 10 ml/min in buffer GF (25 mM
Tris-HCl pH 7.9, 10% (v/v) glycerol, 1 mM DTT, 5 mM MgCl2,
300 mM NaCl). When immunopurified complexes were separated
the GF buffer contained also 50 mg/ml insulin. Forty fractions
(50 ml) were collected and analysed by western blot.
SUPPORTING INFORMATION
Figure S1 Pair wise BestFit alignment between the C-terminal
half of yeast Spt7p and the whole length human SPT7-Like
protein (see O94864 and AAG47636). The amino acid positions in
the different sequences are labelled on the left and on the right.
The peptides identified in hSPT7L by MALDI TOFF mass
spectrometry are shown in bold and with capital letters. When two
peptides follow in a row the trypsin-cutting site is shown by a black
triangle. The putative histone fold domain (HFD) in both proteins
is over layered (according to [1]). Percent similarity between the
two proteins is: 45.98% and percent identity is 22.86%. 1)
Gangloff YG, Sanders SL, Romier C, Kirschner D, Weil PA, et al.
(2001) Histone folds mediate selective heterodimerization of yeast
TAF(II)25 with TFIID components yTAF(II)47 and yTAF(II)65
and with SAGA component ySPT7. Mol Cell Biol 21: 1841–1853
Found at: doi:10.1371/journal.pone.0000316.s001 (0.02 MB
DOC)
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